{"filing":{"accession_number":"0001731122-26-000988","cik":"0001314052","ticker":"AVXL","company_name":"ANAVEX LIFE SCIENCES CORP.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"e7813_8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000988/e7813_8-k.htm"},"events":[{"id":22698,"run_id":20534,"accession_number":"0001731122-26-000988","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing preliminary financial results for the second quarter ended March 31, 2026. The press release (Exhibit 99.1) reports preliminary condensed consolidated interim statements of operations, comprehensive loss, and balance sheets, along with key financial metrics including net loss of $5.3 million for Q2 2026 versus $11.2 million for Q2 2025, and cash position of $127.4 million. The disclosure is material to investors assessing the company's financial condition and runway.","company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22719,"accession_number":"0001731122-26-000988","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing preliminary financial results for the second quarter ended March 31, 2026. The press release (Exhibit 99.1) reports preliminary condensed consolidated interim statements of operations, comprehensive loss, and balance sheets, along with key financial metrics including net loss of $5.3 million for Q2 2026 versus $11.2 million for Q2 2025, and cash position of $127.4 million. The disclosure is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:18:49.490929+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22719,"accession_number":"0001731122-26-000988","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing preliminary financial results for the second quarter ended March 31, 2026. The press release (Exhibit 99.1) reports preliminary condensed consolidated interim statements of operations, comprehensive loss, and balance sheets, along with key financial metrics including net loss of $5.3 million for Q2 2026 versus $11.2 million for Q2 2025, and cash position of $127.4 million. The disclosure is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:18:49.490929+00:00","company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","filing_date":"2026-07-30"}]}